Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2020 – Cholangiocarcinoma
ASCO 2020 – Cholangiocarcinoma
Adjuvant Concurrent Chemoradiotherapy in Extrahepatic Cholangiocarcinoma
ASCO 2020 – Cholangiocarcinoma
The use of adjuvant chemoradiotherapy was associated with improved overall survival compared with chemotherapy alone in patients with resected extrahepatic cholangiocarcinoma.
Read More ›
Retrospective Analysis of Post Second-Line Chemotherapy Outcomes with Advanced or Metastatic CCA and FGFR2 Fusions
ASCO 2020 – Cholangiocarcinoma
In a phase 2 trial of patients with cholangiocarcinoma and
FGFR2
fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.
Read More ›
FOENIX-CCA2: Phase 2, Open-Label, Multicenter Study of Futibatinib in Patients with iCCA Harboring FGFR2 Gene Fusions
ASCO 2020 – Cholangiocarcinoma
Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring
FGFR2
gene fusions or other rearrangements.
Read More ›
Natural History of Fibroblast Growth Factor Receptor–Altered Cholangiocarcinoma
ASCO 2020 – Cholangiocarcinoma
The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review.
Read More ›
Phase 2 Study of mFOLFOX versus mFOLFIRI in Locally Advanced or Metastatic BTC Refractory to First-Line Chemotherapy
ASCO 2020 – Cholangiocarcinoma
This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.
Read More ›
TreeTopp: Randomized Phase 2 Study of Varlitinib plus Capecitabine versus Placebo in Second-Line Advanced or Metastatic BTC
ASCO 2020 – Cholangiocarcinoma
Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer.
Read More ›
Primary Tumor versus Metastatic Tumor Tissue versus Liquid Biopsy in iCCA: A Comparative Comprehensive Genomic Profiling Study
ASCO 2020 – Cholangiocarcinoma
Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma.
Read More ›
IDH1 Mutation Detection in ctDNA and Association with Clinical Response in Patients with Advanced iCCA from Phase 3 ClarIDHy
ASCO 2020 – Cholangiocarcinoma
Detection of
IDH1
mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue.
Read More ›
Phase 2 Study of Nivolumab with Gemcitabine/Cisplatin or Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable BTC (BilT-01)
ASCO 2020 – Cholangiocarcinoma
The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer.
Read More ›
Combination Immunotherapy with Ipilimumab and Nivolumab in Patients with Advanced Biliary Tract Cancer
ASCO 2020 – Cholangiocarcinoma
The response rate to the combination of ipilimumab and nivolumab in patients with advanced biliary tract cancer compared favorably to clinical trials investigating single-agent anti–PD-1 therapy.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us